Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Base Year Market Size (2025) | USD 1.29 Billion |
| Market Size (2026) | USD 1.39 Billion |
| Market Size (2031) | USD 1.98 Billion |
| Growth Rate (2026 - 2031) | 7.36% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Australia Veterinary Healthcare Market Analysis by Mordor Intelligence
The Australia veterinary healthcare market size is expected to grow from USD 1.29 billion in 2025 to USD 1.39 billion in 2026 and is forecast to reach USD 1.98 billion by 2031 at 7.36% CAGR over 2026-2031. Demand is pivoting around mandatory livestock traceability, fast-tracked biologic approvals, and rising companion-animal spending. Electronic identification for sheep and goats couples disease surveillance with data analytics revenue, while point-of-care diagnostics shorten decision cycles and capture margin that once flowed to external laboratories[1].Integrity Systems Company, “NLIS Database Uplift Project,” integritysystems.com.au Private-equity roll-ups equip newly acquired clinics with proprietary analyzers to boost earnings, and sovereign vaccine manufacturing investments protect supply chains from geopolitical disruptions. Workforce shortages in rural areas and price-sensitive pet owners temper growth, yet pet insurance uptake and subscription wellness plans cushion out-of-pocket shocks.
Key Report Takeaways
- By product, therapeutics led with 62.55% of the Australian veterinary healthcare market share in 2025. Diagnostics are projected to expand at a 9.85% CAGR through 2031, the fastest rate among all categories.
- By animal type, dogs and cats generated 45.53% revenue in 2025, while poultry is advancing at an 8.75% CAGR to 2031.
- By route of administration, parenteral products held a 47.15% share in 2025; oral formulations will expand at an 8.82% CAGR during the forecast period.
- By end user, veterinary hospitals and clinics accounted for 54.52% of spending in 2025, whereas point-of-care testing settings are rising at an 8.12% CAGR through 2031.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Australia Veterinary Healthcare Market Trends and Insights
Drivers Impact Analysis*
| Driver | ( ~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Animal-Health Expenditure Among Pet Owners | +1.5% | Major metropolitan areas | Medium term (2-4 years) |
| Expansion of Livestock Export Volumes And Values | +1.3% | QLD, NSW, VIC | Long term (≥ 4 years) |
| Uptake of Advanced Diagnostics | +1.8% | National | Short term (≤ 2 years) |
| Growth in Pet-Insurance Penetration | +0.8% | National | Medium term (2-4 years) |
| APVMA Fast-Track Pathway for Biologics | +0.6% | National | Medium term (2-4 years) |
| Traceability-Linked Demand for eID Health Tech | +1.0% | Sheep-producing states | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising Animal-Health Expenditure Among Pet Owners
Households spend between AUD 1,500 and AUD 3,000 (USD 975 to USD 1,950) per pet per year, with veterinary care accounting for up to 20% of those outlays[2]Australian Veterinary Association, “Veterinary Workforce Survey 2024,” ava.com.au. Insurance penetration climbed by double digits in 2024-2025 and now covers nearly one in five animals, enabling costly interventions such as orthopedic surgery and oncology to proceed without liquidity constraints[3]Australian Veterinary Association, “Veterinary Workforce Survey 2024,” ava.com.au. Telehealth reimbursement lowers barriers to early diagnosis, and corporate wellness subscriptions lock in repeat visits by spreading fees across the year. These mechanisms stabilize clinic revenue and fund investments in diagnostics that reinforce the growth trajectory of the Australian veterinary healthcare market.
Expansion of Livestock Export Volumes and Values
Australia shipped 766,044 head of cattle and 433,078 sheep in 2024, underpinned by livestock product value of AUD 38.6 billion (USD 25.1 billion)[4]ABARES, “Agricultural Commodities Forecasts 2024-25,” agriculture.gov.au . Disease-free status is critical for market access, prompting producers to intensify vaccination and parasite-control programs. Climate volatility heightens parasite load, steering demand toward long-acting injectables and multivalent vaccines that align with extensive grazing practices. China’s reopening to additional Australian plants and Indonesia’s appetite for feeder cattle are expected to boost therapeutics consumption, reinforcing the Australian veterinary healthcare market outlook.
Uptake of Advanced Diagnostics
The April 2024 launch of IDEXX Catalyst One delivers 17-chemistry panels in 10 minutes, eliminating reference-lab delays. Zoetis followed with its AI-driven Vetscan OptiCell hematology platform in December 2024. Faster results improve care quality and allow clinics to capture revenue that would otherwise be ceded to external labs. Corporate chains standardize these analyzers across networks to optimize reagent procurement and technician training, thereby strengthening the profitability of the Australian veterinary healthcare market.
Traceability-Linked Demand for eID-Enabled Health Tech
Electronic identification became compulsory for sheep and goats born after 1 January 2025, with full-flock compliance due by 2027. The National Livestock Identification System database migration to Amazon Web Services supports real-time linkage between movement data and veterinary interventions. Federal and state subsidies covering tag and reader costs spur adoption, while software overlays convert compliance into predictive health analytics, an emerging revenue stream inside the Australian veterinary healthcare market.
Restraints Impact Analysis*
| Restraint | (~ ) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost of Veterinary Services And Pharmaceuticals | –0.8% | National | Short term (≤ 2 years) |
| Stringent, Evolving Regulatory Processes | –0.4% | National | Long term (≥ 4 years) |
| Rural Workforce Shortages | –0.6% | Regional and remote areas | Long term (≥ 4 years) |
| Counterfeit and Grey-Market Medicines Online | –0.3% | National | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
High Cost of Veterinary Services and Pharmaceuticals
Consultation fees rose by 91% in 2024, pushing routine visits to AUD 80-150 (USD 52-98) and emergency care to AUD 200-500 (USD 130-325). Complex surgeries now exceed AUD 5,000 (USD 3,250), deterring price-sensitive owners and delaying care. Unregulated online channels market discounted, often unregistered drugs, siphoning revenue from legitimate suppliers and creating compliance risks. These pressures moderate near-term expansion of the Australian veterinary healthcare market.
Rural Workforce Shortages Limiting Service Access
One in three veterinary roles outside metropolitan areas remained vacant in 2025. Government incentives totaling AUD 10.6 million (USD 6.9 million) address relocation and loan forgiveness, yet professional isolation and limited career paths persist. Telemedicine offers triage support but cannot replace hands-on procedures, keeping service gaps wide and capping growth potential in livestock-intensive regions that otherwise would enlarge the Australian veterinary healthcare market.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Product: Diagnostics Capture Fastest Upside
Diagnostics started from a smaller base yet are growing at a 9.85% CAGR, outpacing therapeutics, which held 62.55% of the Australian veterinary healthcare market share in 2025. Point-of-care chemistry and hematology systems shorten turnaround to minutes and keep revenue in-house, lifting clinic profitability. Vaccines dominate therapeutics, with combination shots reducing visits and enhancing compliance. Parasiticides gain from tick range expansion, while antimicrobial stewardship tempers anti-infective use.
Diagnostic imaging remains capital-intensive, yet corporate chains deploy radiography and ultrasound to differentiate their services. Molecular PCR panels gained poultry traction amid avian-influenza vigilance, compressing detection from 48 hours to 4 hours and reinforcing demand across the Australia veterinary healthcare market.
By Animal Type: Poultry Leads Growth Curve
Dogs and cats accounted for 45.53% of 2025 revenue, reflecting high pet ownership, but poultry is forecast to grow at an 8.75% CAGR as biosecurity investments scale. Mandatory surveillance and hatchery vaccination protect a sector that produces 1.3 million tonnes of meat annually, anchoring the uptake of therapeutics and diagnostics. Equine and swine remain niche yet high-value, while sheep and goats benefit from electronic identification that tightens residue compliance, broadening opportunities across the Australia veterinary healthcare market size for these subsegments
By Route of Administration: Oral Formulations Gain Traction
Parenteral formats held 47.15% share in 2025, but oral products are rising at 8.82% CAGR as taste-masked chewables boost adherence. Long-acting injectables remain essential for large-scale cattle operations that require documented dosing for export certification. Spot-on topicals face scrutiny over environmental runoff, prompting label reviews. Continued improvements in palatability will increase oral uptake and diversify revenue in the Australian veterinary healthcare market.
By End User: Point-of-Care Testing Accelerates
Hospitals and clinics captured 54.52% spending in 2025, yet in-house testing sites are scaling at an 8.12% CAGR as analyzers replicate reference-lab menus at lower cost. Corporate consolidators standardize workflows to leverage reagent purchasing power, while academic centers focus on surveillance and research. Reference labs retain complex assays but must retool services to defend share amid the in-practice migration reshaping the Australia veterinary healthcare market.
Regulatory Landscape
Australia regulates veterinary chemical products under the National Registration Scheme for Agricultural and Veterinary Chemicals (NRS), with the Australian Pesticides and Veterinary Medicines Authority (APVMA) assessing, registering, and regulating products up to the point of retail sale. After-sale use is controlled by state and territory agencies, which creates a two-stage compliance environment that shapes labeling, distribution, and on-farm use. Key enabling legislation includes the Agricultural and Veterinary Chemicals (Administration) Act 1992 and the Agricultural and Veterinary Chemicals Code Act 1994.
Imports generally require registered products and approved active constituents unless an exemption applies. Manufacturers supplying export markets must also meet APVMA licensing requirements for Australian sites producing finished products or intermediates for export. In June 2024, the Public Governance, Performance and Accountability (Location of Corporate Commonwealth Entities) Repeal Order 2024 removed location restrictions for the APVMA, giving the agency more operational flexibility that can affect how sponsors and manufacturers engage during review, manufacturing, and export-certificate processes.
Competitive Landscape
The Australia veterinary healthcare market reports moderate consolidation as private equity inflows chase scale economies and brand leverage. EQT’s acquisition of VetPartners in January 2025 created a 267-clinic network employing more than 1,300 veterinarians, intensifying bargaining power with suppliers and accelerating protocol standardization. Greencross, valued at USD 3.75 billion, evaluates an ASX relisting to unlock capital for digital initiatives and clinic refurbishments. U.K.-based CVS Group invested USD 82.5 million to secure 28 Australian sites, signaling continued cross-border interest in local assets.
Pharmaceutical manufacturers expand production footprints to secure supply sovereignty. Zoetis purchased a 21-acre plant in Melbourne in August 2024, doubling its vaccine output and aligning with government calls for domestic vaccine production. Technology vendors differentiate practices: 30% of clinicians now rely on AI diagnostics to shorten wait times and elevate accuracy, appealing to quality-conscious owners. Practice management software providers integrate compliance modules that ease APVMA documentation, lowering administrative burdens and sharpening competitive positioning.
White-space remains in remote service delivery. Telehealth triage, mobile surgical units, and subscription wellness plans aim to bridge clinician gaps in the outback while generating recurring revenue. Workforce initiatives focus on retention bonuses and mental health support to curb attrition. As consolidation continues, the Australia veterinary healthcare market will likely reach an equilibrium where a handful of corporate groups coexist with high-touch independents that command localized loyalty.
Australia Veterinary Healthcare Industry Leaders
Zoetis Inc
Merck Co. Inc.
Elanco Animal Health
Boehringer Ingelheim Animal Health
Virbac
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Biosecurity-driven surveillance and diagnostics workflows form a clear whitespace area. Mainland Australia recorded a first detection of H5 high pathogenicity avian influenza (HPAI) in June 2026, and July 2026 guidance urged reducing contact between poultry and wild birds, including advice for free-range producers to keep flocks indoors where practical. These developments support demand for rapid in-practice testing, flock health monitoring, and outbreak-response protocols across poultry supply chains, and they also raise the premium on clinic capacity and mobile or remote service models in regions where workforce gaps persist.
Another opportunity is the move toward standardized stewardship and lower-resistance tools, backed by CSIROs April 2026 Animal Antimicrobial Stewardship Framework across 18 focus areas for veterinarians and animal managers. This provides room for companies to bundle therapeutics with decision-support, audit-ready documentation, and practice management integrations that simplify pharmacovigilance and prescribing governance. Innovation programs, including Australian Wool Innovations July 2026 trials of a tea-tree oil biopesticide using nanotechnology to treat flystrike, also point to more differentiated parasiticide alternatives for sheep-producing states where residue and resistance concerns remain central, complementing traceability-linked compliance requirements expanding on-farm data capture.
Recent Industry Developments
- June 2026: Merck & Co., Inc. (Merck Animal Health) announced a definitive agreement to acquire TARGAN, a developer of biodevice solutions for the poultry industry. The deal expands Merck's technology footprint in production-animal health and links device-led automation more closely to health outcomes in intensive poultry operations, where surveillance and biosecurity investment is rising.
- January 2025: Zoetis announced the global rollout of its cartridge-based, AI-powered Vetscan OptiCell hematology analyzer, with initial installations including Australia. Faster, standardized hematology supports the shift of diagnostics into veterinary hospitals, clinics, and in-house testing settings, helping corporate networks and independents capture revenue previously directed to reference laboratories.
- March 2024: Zoetis purchased a 21-acre manufacturing site in Melbourne, Victoria, to expand local operations and vaccine manufacturing capability for livestock and companion animals. The investment strengthens domestic supply resilience and supports faster replenishment for immunization programs that underpin export-market access and companion-animal preventive care.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market measures spending in Australia on veterinary healthcare products and solutions used to prevent, diagnose, and treat animal health conditions across common companion and farm animal populations, reported in USD value terms.
Scope exclusions: Human healthcare, pet food, pet insurance, and non-medical pet accessories are excluded from the market totals.
Segmentation Overview
- By Product
- Therapeutics
- Vaccines
- Parasiticides
- Anti-Infectives
- Medical Feed Additives
- Other Therapeutics
- Diagnostics
- Immunodiagnostic Tests
- Molecular Diagnostics
- Diagnostic Imaging
- Clinical Chemistry
- Point-of-Care Testing Devices
- Therapeutics
- By Animal Type
- Dogs and Cats
- Horses
- Swine
- Poultry
- Other Animal Types
- By Route of Administration
- Oral
- Parenteral
- Topical
- Others
- By End User
- Veterinary Hospitals & Clinics
- Reference Laboratories
- Point-of-Care / In-House Testing Settings
- Academic & Research Institutes
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to set the market boundaries, align terminology, and anchor the model to real world animal health signals in Australia. We reviewed public sources such as the Australian Bureau of Statistics for macro indicators, the Department of Agriculture, Fisheries and Forestry for biosecurity and livestock context, and the Australian Pesticides and Veterinary Medicines Authority for product and regulatory references.
To keep assumptions practical, additional inputs were pulled from sources such as peer-reviewed veterinary journals, trade association publications, company annual reports and investor presentations, and reputable press coverage tied to clinic activity and animal ownership trends. Where it helped close gaps in company-level revenues or product footprint, we also referenced paid subscriptions focused on company financials and intelligence, and patent databases for innovation direction checks. These desk research sources are illustrative, and many other public and paid sources were also used for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work focused on validating what is actually being purchased and used across the country, and how pricing and volumes are moving for core veterinary therapeutics and diagnostics. We spoke with a mix of veterinary hospitals and clinics, diagnostic labs and in-house testing users, and suppliers and channel participants to test demand drivers, adoption patterns, and the realism of growth assumptions across major Australian states.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 34% | CXOs: 14% | |
| Mid tier: 50% | Functional/Unit leaders: 39% | |
| Smaller Players: 16% | Managers: 47% |
Market-Sizing & Forecasting
Sizing starts from a top-down build where animal populations and treated incidence are translated into a demand pool, which is then valued using typical treatment rates and diagnostic utilization in Australia. To keep totals grounded, selective bottom-up checks are run using sampled supplier and clinic revenues, plus a simple volume times average selling price logic for common therapy classes and test categories, and then the model is adjusted if the two views disagree.
Inputs used in the model include indicators such as companion animal ownership and clinic visitation patterns, livestock herd and flock dynamics, preventive care intensity (vaccination and parasite control), uptake of point-of-care and reference lab testing, and average price movement for key product baskets. When data is missing for smaller channels or less visible use cases, we apply conservative penetration assumptions and then test them in interviews before they are carried into the final totals.
For forecasting, scenario analysis is used so the outlook reflects different paths for clinic capacity, wage and cost pressures, and the speed of diagnostics adoption, while still staying consistent with the base demand pool. Growth rates are finalized only after interview feedback is mapped back to the measurable variables used in the model.
Data Validation & Update Cycle
Outputs are triangulated across multiple signals so single-source bias is reduced, and we check for year-to-year breaks that do not match what practitioners report on pricing, throughput, or product availability. Variance checks are performed across animal types and care settings, and any outliers trigger a second pass on assumptions, followed by re-contact with selected respondents when the explanation is not clear.
Before sign-off, the model goes through multi-step analyst review so definitions, conversions, and math are consistent from input tables to final totals. Reports are refreshed annually, with interim updates when there are material events that can change demand or pricing, and a final freshness check is completed right before delivery.
Mordor Intelligence's Australia Veterinary Healthcare Market Market Size Versus Other Published Estimates
Published market sizes for Australia veterinary healthcare can look far apart because the underlying scope is not always the same, and the demand signals picked to value the market can also vary. Differences usually come from whether services are included, what animal populations are emphasized, and how quickly pricing is assumed to move over time.
By tracking treated-animal demand signals and refreshing product-to-service boundaries during model reviews, Mordor Intelligence keeps the estimate centered on therapeutics and diagnostics spending rather than folding in the broader veterinary services revenue pool. Some estimates also start from clinic revenue totals and then allocate backward, which can inflate or deflate the number depending on how grooming, boarding, and other non-medical line items are handled, and how currency timing is applied.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 1.29 B (2025) | |
| Industry Data Provider A | USD 1.79 B (2023) | This estimate is built around veterinary medical services revenue, which typically includes clinic-delivered services and add-on offerings that sit outside products-focused healthcare totals. The earlier base year and different service mix assumptions can also shift the value versus a products-led definition. |
| Industry Intelligence Publisher B | USD 5.70 B (2026) | This figure reflects the veterinary services industry and is structurally broader than veterinary healthcare products and diagnostics, so it captures labor-intensive service revenue and emergency and planned care billing. The scope choice alone can create a multi-billion-dollar spread even when underlying animal health demand trends are similar. |
The comparison mainly shows a scope boundary gap, where service-heavy definitions naturally land higher than a therapeutics-and-diagnostics view. When buyers align the included revenue streams, the remaining differences usually come from base-year selection, pricing progression methods, and how aggressively utilization growth is assumed.
Key Questions Answered in the Report
How fast is the Australia veterinary healthcare market growing?
The market is expanding at 7.36% CAGR between 2026 and 2031, moving from USD 1.39 billion in 2026 to USD 1.98 billion by 2031.
Which product category is expanding the quickest?
Diagnostics are projected to grow at 9.85% CAGR through 2031, driven by point-of-care analyzers and molecular tests.
What animal segment shows the highest future growth?
Poultry health solutions are forecast to increase at 8.75% CAGR due to heightened biosecurity and surveillance spending.
Why are oral formulations gaining share?
Palatability innovations in chewable parasiticides improve adherence, pushing oral products toward an 8.82% CAGR.
How does traceability affect livestock health investment?
Mandatory electronic identification links movement data with treatment history, boosting demand for data analytics and compliance-driven therapeutics.
Which companies are leading consolidation of veterinary clinics?
CVS Group and VetPartners, backed by private equity, are the most active consolidators, collectively controlling hundreds of practices nationwide.
Page last updated on:
